Hemab Therapeutics Starts Phase 3 Trial of Sutacimig for Glanzmann Thrombasthenia

• Hemab Therapeutics initiated SOLARA, a pivotal Phase 3 trial of once-weekly sutacimig to prevent bleeding in people with Glanzmann thrombasthenia.
• Approximately 75 participants will undergo a 24-week observation period followed by 48 weeks of treatment, comparing treated bleeding rates within each participant.
• The single-arm design proceeds despite FDA advice to consider a randomized trial, reflecting concerns about feasibility in the rare disorder.
• Phase 2 results already presented at the ISTH 2026 Congress showed reduced treated bleeding; most adverse events were mild or moderate.
• Three participants experienced thromboembolic events; SOLARA’s dosing was selected to avoid high peak exposures linked to those events.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hemab Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090700PRIMZONEFULLFEED9872715) on November 09, 2026, and is solely responsible for the information contained therein.